[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cohort-studies\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cohort-studies":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,54,92,112,141,168,195,222],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100635380","womens-reproductive-choices-and-mental-health-during-pregnancy-and-after-birth-in-wartime-ukraine-100635380",false,"NCT07551934","Women's Reproductive Choices and Mental Health During Pregnancy and After Birth in Wartime Ukraine","Integrative Model of Factors Influencing Reproductive Behavior and Perinatal Mental Health of Women Amidst War","Inclusion Criteria:\n\n* able and willing to provide informed consent;\n* aged 18 years or older.\n\nExclusion Criteria:\n\n* younger than 18 years;\n* unable to provide informed consent;\n* do not have sufficient language proficiency to complete the study procedures;\n* at the time of recruitment, they have an acute medical or psychological condition that would make participation unsafe, inappropriate, or unduly burdensome (e.g., obstetric emergencies, immediate postoperative or critical care status, or severe acute distress requiring urgent clinical care);\n* participation or the handling of personal data could reasonably pose a risk to the safety of the participant or their family.",true,"ALL","18 Years",{"count":20,"type":21},328,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn how war affects reproductive decisions and perinatal mental health in Ukrainian women.\n\nThe main questions it aims to answer are: (1) how are wartime stress and trauma related to women's decisions about pregnancy and childbirth?; (2) what mental health symptoms and psychological difficulties are experienced during the perinatal period under wartime conditions? (3) which demographic, obstetric, and psychological factors are linked to poorer mental health and childbirth experiences?\n\nResearchers will survey at least 300 women.\n\nParticipants will: (1) complete questionnaires about their mental health and psychological well-being; (2) answer questions about their reproductive choices, pregnancy, and\u002For childbirth experiences; (3) report on the impact of war, social support, maternal care, and postpartum trauma; (4) provide demographic and obstetric information.\n\nThe findings will be used to develop an evidence-based model of the factors influencing reproductive behavior and perinatal mental health during war.",[25,26,27,28],"Perinatal Mental Health","Reproductive Behavior","Women","Cohort Studies",[30,31,32,33,34,35,36,37,38,39,40],"perinatal psychology","mental health","reproductive behavior","psychological trauma","PTSD","CB-PTSD","postpartum depression","pregnancy","sexual health","Ukraine","war-affected population","NOT_YET_RECRUITING","2026-05-04",{"date":44,"type":45},"2026-05-08","ACTUAL",{"date":47,"type":21},"2026-06",{"date":49,"type":21},"2028-11",{"name":51,"class":52},"Taras Shevchenko National University of Kyiv","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":60,"targetDuration":62,"studyType":22,"phases":4,"briefSummary":63,"conditions":64,"keywords":80,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":88,"leadSponsor":90,"locationsCount":53},"100630525","natural-history-study-for-patients-with-nemaline-myopathy-in-spain-100630525","NCT07488806","Natural History Study for Patients With Nemaline Myopathy in Spain","Inclusion Criteria:\n\n* Patients with a confirmed clinical and genetic diagnosis of MN (mutations in ACTA1, NEB, TPM2, TPM3, KBTBD13, CFL2, KLHL40, KLHL41, LMOD3, MYPN, TNNT1, TNNT3), or under discussion if they only have a compatible biopsy.\n* Signed informed consent by the patient or Legal Authority Responsible, and\u002For assent by the subject (in pediatric population).",{"count":61,"type":21},100,"5 Years","The objective of this natural history study is to comprehensively characterize the disease progression and clinical features of nemaline myopathies. The study aims to establish a well-defined cohort of patients in Spain, enabling long-term follow-up and facilitating recruitment for future clinical trials.",[65,66,67,68,69,70,71,72,73,74,75,76,77,28,78,79],"Nemaline Myopathy","Myopathies","Myopathic Conditions","NEB","ACTA1","TPM2","TPM3","TNNT1","CFL2","KBTBD13","KLHL40","KLHL41","LMOD3","MYPN","TNNT3",[81,82],"NATURAL HISTORY","NEMALINE MYOPATHY","RECRUITING","2026-03-18",{"date":86,"type":45},"2026-03-23",{"date":47,"type":21},{"date":89,"type":21},"2032-06",{"name":91,"class":52},"Hospital Universitari Vall d'Hebron Research Institute",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":4},"100589980","ai-assisted-quality-control-study-of-multimodal-data-in-the-epidemiological-survey-of-shanghai-nicheng-cohort-study-100589980","NCT06961461","AI-assisted Quality Control Study of Multimodal Data in the Epidemiological Survey of Shanghai Nicheng Cohort Study","Inclusion Criteria:\n\n1. Be proficient in using computers;\n2. The person responsible for questionnaire quality control needs to have good dialect recognition ability;\n3. Have a basic understanding or high acceptance of AI-assisted tools, and be able to adapt to the learning and application of new technologies\n4. Be able to participate in the research throughout the process, abide by the research process, receive training, and be willing to complete quality control tasks as required.\n\nExclusion Criteria:\n\n1. The person responsible for questionnaire quality control cannot understand or recognize Shanghai Nanhui dialect proficiently;\n2. Unfamiliar with AI-assisted tools and difficult to accept technical operations;\n3. Unable to participate in the research, receive training or complete the specified tasks due to other work or academic reasons;",{"count":99,"type":21},900,"This study is based on the Nicheng Cohort study. This study intends to analyze whether AI assistance can effectively improve the efficiency and accuracy of quality control of data collected in large-scale epidemiological surveys based on traditional quality control processes.",[102,28],"Quality Control","2025-04-29",{"date":105,"type":45},"2025-05-08",{"date":107,"type":21},"2025-05-01",{"date":109,"type":21},"2025-08-15",{"name":111,"class":52},"Shanghai 6th People's Hospital",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":17,"minAge":118,"maxAge":119,"enrollmentInfo":120,"targetDuration":62,"studyType":22,"phases":4,"briefSummary":121,"conditions":122,"keywords":127,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":53},"100587110","spanish-natural-history-study-for-lama2-muscular-dystrophy-100587110","NCT06924125","Spanish Natural History Study for LAMA2 Muscular Dystrophy","Inclusion Criteria:\n\n* All patients with compatible clinical presentation and identification of 2 pathogenic variants in LAMA2, or muscle biopsy with decreased laminin alpha2 protein and at least one pathogenic variant\n* Signed informed consent by the Legal Authority Responsible and\u002For assent by the subject (starting from 6 years old)","0 Minutes","100 Years",{"count":61,"type":21},"The objective of this natural history study is to comprehensively characterize the disease progression and clinical features of LAMA2-related dystrophies (LAMA2-RD) in the pediatric population. The study aims to establish a well-defined cohort of patients in Spain, enabling long-term follow-up and facilitating recruitment for future clinical trials.",[123,124,125,126,28],"LAMA2-MD (Merosin Deficient Congenital Muscular Dystrophy, MDC1A)","Merosin Deficient CMD (Full or Partial)","Merosin Deficient Congenital Muscular Dystrophy","Muscular Dystrophies",[128,129,130,131,132],"Merosin","LAMA2","Laminin","Dystrophy","natural history","2025-04-05",{"date":135,"type":45},"2025-04-11",{"date":137,"type":45},"2021-07-27",{"date":139,"type":21},"2030-07-01",{"name":91,"class":52},{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":151,"conditions":152,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":53},"100505006","nationwide-uniform-scientific-evaluation-of-flexible-and-integrated-treatment-projects-from-2022-onwards-100505006","NCT05855720","Nationwide Uniform Scientific Evaluation of Flexible and Integrated Treatment Projects From 2022 Onwards","Bundesweit Einheitliche Wissenschaftliche Evaluation Von Modellvorhaben Nach § 64b SGB V ab 2022","EVA64_2","Inclusion Criteria:\n\n* treatment in any of the participating hospitals or control hospitals within recruitment phase (number of hospitals will be fix until June 2026)\n* being insured with any of the participating SHI funds\n\nExclusion Criteria:\n\n* less than one year follow-up data available",{"count":150,"type":21},30000,"This study is an evaluation of flexible and integrated psychiatric care models (according to § 64b of the German Social Code Book V (SGB V)) (FIT) including new FIT projects starting after 2022 and the prolongation of any of 19 already established FIT projects (mainly at German psychiatric hospitals). The central concern of this evaluation is to answer the question whether FIT care offers advantages over standard care. The orientation of model care is a more cross-sectoral provision of services through more flexible psychiatric treatment intensities. However, FIT program structures depend on the individual situation and organization of the FIT hospital together with the participating statutory health insurance (SHI) funds.",[153,154,155,156,157,158,28],"Mental Health","Cross-sectoral Treatment","Flexible and Integrated Treatment","FIT","Psychiatry","Evaluation Study","2024-08-06",{"date":161,"type":45},"2024-08-07",{"date":163,"type":45},"2019-01-01",{"date":165,"type":21},"2041-07",{"name":167,"class":52},"Technische Universität Dresden",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":177,"phases":178,"briefSummary":180,"conditions":181,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":53},"100509658","family-inheritance-gene-gene-and-gene-environment-interactions-in-the-field-of-cardiovascular-and-renal-diseases-fifth-visit-of-the-stanislas-cohort-100509658","NCT05916287","FAMILY INHERITANCE, GENE-GENE AND GENE-ENVIRONMENT INTERACTIONS IN THE FIELD OF CARDIOVASCULAR AND RENAL DISEASES. Fifth Visit of the STANISLAS Cohort","HÉRITABILITÉ FAMILIALE, INTERACTIONS GÈNE-GÈNE ET GÈNE-ENVIRONNEMENT DANS LE DOMAINE DES MALADIES CARDIOVASCULAIRES ET RENALES. Cinquième Visite de la Cohorte STANISLAS","Inclusion Criteria:\n\n* aged over 18\n* Person who participated in the Stanislas Cohort\n* Person affiliated to a social security scheme or beneficiary of such a scheme\n* Person having received complete information on the organization of the research and having signed an informed consent\n\nExclusion Criteria:\n\n* Persons deprived of their liberty by a judicial or administrative decision, persons undergoing psychiatric treatment under Articles L. 3212-1 and L. 3213-1\n* Person referred to in Articles L. 1121-5, L. 1121-7 and L1121-8 of the Public Health Code:\n\n  * Pregnant woman, parturient or nursing mother\n  * Adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice)\n  * Person of full age unable to express consent",{"count":176,"type":21},3000,"INTERVENTIONAL",[179],"NA","The Stanislas Cohort is a monocentric familial longitudinal cohort originally comprised of 1006 families consisting of two parents and at least two biological children and deemed healthy, recruited in 1993-1995 at the Centre for Preventive Medicine of Nancy. This cohort was established with the primary objective of investigating gene-gene and gene-environment interactions in the field of cardiovascular diseases. The 5th visit of the STANISLAS Cohort will allow a better evaluation of the cardiovascular ageing of the population and the transition toward cardiovascular or renal diseases in relation with their genetic profile and environment.",[182,28,183,184,185],"Cardiovascular Diseases","Genotype","Risk Factors","Nutrition","2023-08-11",{"date":188,"type":45},"2023-08-15",{"date":190,"type":45},"2023-07-13",{"date":192,"type":21},"2027-07-13",{"name":194,"class":52},"Central Hospital, Nancy, France",{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":201,"enrollmentInfo":202,"targetDuration":4,"studyType":177,"phases":204,"briefSummary":206,"conditions":207,"keywords":208,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":53},"100494084","early-phase-1-efficacy-and-safety-of-apantamide-combined-with-docetaxel-and-adt-vs-apantamide-combined-with-adt-in-patients-with-high-tumor-burden-mhspc-a-multicenter-and-prospective-cohort-study-100494084","NCT05713578","Efficacy and Safety of Apantamide Combined With Docetaxel and ADT vs. Apantamide Combined With ADT in Patients With High Tumor Burden mHSPC: a Multicenter and Prospective Cohort Study","Inclusion Criteria:\n\n1. Age ≥ 18 years, male;\n2. It was diagnosed as prostate adenocarcinoma by histological or cytological examination, and its pathological type was adenocarcinoma;\n3. Bone imaging, CT or MRI showed ≥ 4 bone metastases (≥ 1 bone metastasis located outside the pelvis or spine) or visceral metastasis;\n4. .Patients with recurrence after new or local treatment are sensitive to endocrine therapy;\n5. Patients receiving ADT treatment (drug or surgical castration), with or without the first generation of antiandrogen drugs, for no more than 3 months, and without evidence of soft tissue imaging disease progression (according to RECIST 1.1 standard) or clinically significant PSA increase (after serum testosterone reaches the castration level, PSA increases by 50% from the lowest level), are allowed to be included in the group;\n6. Plan to receive docetaxel combined with apantamide and ADT or apantamide combined with ADT;\n7. ECOG PS score 0-1;\n8. Adequate hematology and organ function:\n\n   Adequate bone marrow function (no blood transfusion, no use of granulocyte colony stimulating factor): absolute neutrophil count (ANC) ≥ 1.5 × 109\u002FL（1500\u002F μ L）； Hemoglobin ≥ 90 g\u002FL (9.0 g\u002FdL); Platelet count ≥ 100 × 109\u002FL（100, 000\u002F μ L）；\n\n   Adequate liver function: total bilirubin (TBIL) ≤ 1.5 × ULN； AST, ALT and alkaline phosphatase (ALP) ≤ 2.5 times the upper limit of normal value (ULN);\n\n   Adequate renal function: serum creatinine ≤ 1.5 times the upper limit of normal (ULN) or calculated creatinine clearance ≥ 30 mL\u002Fmin (calculated using Cockcroft Gault formula);\n9. Sufficient coagulation function (without anticoagulation treatment): International normalized ratio (INR) ≤ 1.5;\n\nExclusion Criteria:\n\n1. Have a history of hypersensitivity or intolerance to any drug used in the study;\n2. Plan to receive any other anti-tumor treatment during the study period;\n3. Patients who have received the second generation of androgen receptor (AR) inhibitors in the past, such as apantamide, enzalutamide, darotamide (ODM-201) or other AR inhibitors, CYP17 enzyme inhibitors, such as abietron acetate or oral ketoconazole, chemotherapy or immunotherapy, as well as adjuvant or new adjuvant therapy, should also be excluded;\n4. Four weeks before the start of the study, he received plant drugs (such as saw palmetto) that have the effect of anti prostate cancer or reducing PSA level;\n5. Have a history of epileptic seizures, a history of medication that can reduce the threshold of epileptic seizures, or a disease that can induce epileptic seizures within 12 months before the start of the study and treatment (including a history of transient ischemic attacks, cerebral apoplexy, brain trauma and disturbance of consciousness requiring hospitalization);\n6. There were active heart diseases within 6 months before the start of study treatment, including severe\u002Funstable angina, myocardial infarction, congestive heart failure \\[NYHA III or IV\\], or arrhythmias requiring drug treatment;\n7. There is inability to swallow, chronic diarrhea, intestinal obstruction or other factors affecting drug administration and absorption;\n8. Have a history of immunodeficiency (including HIV test positive, other acquired and congenital immunodeficiency diseases) or organ transplantation;\n9. Known brain metastasis;\n10. Malignant tumors other than prostate cancer in the past 5 years or at the same time, except for cured skin basal cell carcinoma and cervical carcinoma in situ;\n11. Those who are receiving any other experimental drugs or experimental medical devices;\n12. Poor compliance, difficult to cooperate with treatment and follow-up;\n13. The investigator believes that the patient has concomitant diseases (such as poorly controlled hypertension, serious diabetes, neurological or mental diseases, etc.) that seriously endanger the patient's safety, may confuse the research results, or affect the patient to complete the study, or any other situation.","90 Years",{"count":203,"type":21},220,[205],"EARLY_PHASE1","This is a multicenter, prospective, cohort study to evaluate the efficacy and safety of apantamide+docetaxel+ADT versus apantamide+ADT in the treatment of patients with high tumor mHSPC.220 patients with high tumor mHSPC will be included and divided into two treatment groups according to the treatment plan:Treatment group 1: apantamide+docetaxel+ADT,Treatment group 2: apantamide+ADT treatment.The study continued treatment until the patient could not obtain clinical benefits or had intolerable toxic reactions or the patient withdrew the informed consent, whichever occurred first.",[28],[209,210,211,212],"cohort study","apantamide","docetaxel","ADT","2023-02-03",{"date":215,"type":45},"2023-02-06",{"date":217,"type":21},"2023-03-01",{"date":219,"type":21},"2026-12-01",{"name":221,"class":52},"Qilu Hospital of Shandong University",{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":16,"sex":17,"minAge":229,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":232,"conditions":233,"keywords":243,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":53},"100311532","the-nutrinet-sant-study-100311532","NCT03335644","The NutriNet-Santé Study","The NutriNet-Santé Study. A Web-based Prospective Cohort Study of the Relationship Between Nutrition and Health and of Dietary Patterns and Nutritional Status Predictors","Inclusion Criteria:\n\n* aged over 15 years\n* access to internet\n\nExclusion Criteria:\n\n* aged under 15 years","15 Years",{"count":231,"type":21},170000,"The NutriNet-Santé study was set up to investigate nutrition and health relationships. Specifically, it was the first web-based cohort worldwide on such a large scale (n=171 000 as of 2021) focused on the complex link between nutrition and health status. It is characterized by a very detailed assessment of nutritional exposure and dietary behavior.\n\nhttps:\u002F\u002Fetude-nutrinet-sante.fr\u002F https:\u002F\u002Finfo.etude-nutrinet-sante.fr\u002Fen",[234,235,236,28,237,238,239,240,241,242],"Diet, Food, and Nutrition","Exercise","Diseases Category","Adult","Anthropometry","Humans","Internet","Surveys and Questionnaires","Mortality",[244,245,246,247,248,249,250,251,252,253,254,255,256,257,258],"determinants of dietary patterns and nutritional status","Food additives, Food processing","Exclusion diets, vegetarian diet, vegan diet","Organic food, pesticide exposure, sustainability","Gut microbiota","Food labeling","Dietary supplements","Food based dietary guidelines","Psychological determinants of food behavior","Geographical determinants of food behavior","Breastfeeding","Mental health","Cancer","Cardiovascular and cardiometabolic health","Multimorbidity","2021-07-22",{"date":261,"type":45},"2021-07-26",{"date":263,"type":45},"2009-05-11",{"date":265,"type":21},"2029-05-11",{"name":267,"class":52},"University of Paris 13"]